Amgen

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

TeneoBio, Inc. is a biotechnology company focused on developing a new class of biologics known as Human Heavy Chain Antibodies (UniAbs) for therapeutic applications in cancer, autoimmunity, and infectious diseases. Founded in 2009 and based in Menlo Park, California, TeneoBio utilizes its proprietary UniRat technology, which is a transgenic rat designed for heavy chain antibody production. The company employs a sequence-based discovery approach that leverages next-generation sequencing, bioinformatics, and high-throughput recombinant protein expression to identify diverse UniAb leads. TeneoBio's product pipeline includes therapies aimed at multiple myeloma, prostate cancer, immune disorders, and AIDS, with several candidates currently in preclinical development. The company has also created bispecific therapeutic antibodies targeting human CD3 and various tumor antigens, as well as high-affinity blockers for immune checkpoint inhibitors, positioning itself within the evolving field of immune-oncology. The unique properties of UniAbs—characterized by high affinity and versatility—enable the development of innovative therapeutics with enhanced potency and extended half-life.

Rodeo Therapeutics Corp. is a drug development company based in Seattle, Washington, focused on creating novel small molecule therapies aimed at treating inflammatory bowel disease and enhancing blood cell reconstitution after bone marrow transplants. Founded in 2017, the company specializes in targeting specific enzymes and biological pathways that are vital for tissue repair and regeneration. Its therapies work by increasing tissue levels of prostaglandin PGE2 through the inhibition of a prostaglandin-degrading enzyme, thereby facilitating tissue regeneration and protecting against conditions such as colitis. Rodeo Therapeutics is dedicated to advancing treatments that improve patient outcomes in various medical conditions related to tissue damage and recovery.

Five Prime Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in the discovery and development of innovative protein therapeutics. The company is advancing several product candidates, including Bemarituzumab, an antibody targeting fibroblast growth factor receptor 2b, which is currently in Phase 3 trials for gastric and gastroesophageal junction cancers. Other candidates include FPA150, a CD8 T cell checkpoint inhibitor in Phase 1a/1b trials for various cancers, and FPT155, a soluble CD80 fusion protein aimed at enhancing T cell co-stimulation. Additionally, Cabiralizumab, which targets the colony stimulating factor-1 receptor, is being tested in Phase Ia/Ib trials in combination with Opdivo for cancer treatment. Five Prime also has BMS-986258, an anti-TIGIT antibody in Phase 1/2 trials. The company employs a unique ProScreen Engine that enables efficient production and screening of therapeutic proteins, allowing for a more comprehensive approach than traditional methods. Five Prime has established collaborations and licensing agreements with several prominent pharmaceutical companies, enhancing its research capabilities and market reach.

Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.

Keck Graduate Institute (KGI) is part of the prestigious Claremont college system, in Claremont, California. Keck is one of the few graduate schools exclusively dedicated to the study of biosciences. The school’s graduate programs blend academics with business-oriented approaches to the field. KGI awards master’s degrees, certificates and post-doctoral degrees in Biosciences and Biosciences Management. The school also offers degrees in Applied Life Sciences. Students receive a comprehensive education that integrates science, technology and management skills. Learning methods are also comprehensive and include scientific research and mentorship from outside professionals. Visiting mentors work in various capacities within the biosciences industry. This diverse education leads to diverse employment among graduates. Some of the areas in which graduates work include: * Medical diagnostics * Market research * Food technology * Medical writing * Pharmaceutical sales * Vaccine research * Biofuels development Admissions requirements include submission of transcripts, a resume, an essay, a personal statement and lists of references. Applicants are encouraged to apply for tuition fellowships, which can cover up to a substantial amount of KGI’s tuition. Students may also apply for federal loans. Federal loans require the FAFSA, while fellowships require a separate application. Keck Graduate Institute also honors the GI Bill, through which veterans may receive a tuition waiver.

Otezla® is a prescription medicine approved for the treatment of patients with moderate

BeiGene, Ltd. is a biotechnology company engaged in the development and commercialization of targeted and immuno-oncology therapies for cancer. Founded in 2010 and based in Beijing, the company operates globally, focusing on addressing significant unmet medical needs across various cancer types. Its commercial portfolio includes treatments such as BRUKINSA for mantle cell lymphoma and Tislelizumab for Hodgkin's lymphoma, alongside other therapies for conditions like breast cancer and multiple myeloma. BeiGene's pipeline features several clinical-stage drug candidates, including Zanubrutinib, an inhibitor targeting Bruton's tyrosine kinase, and Pamiparib, a PARP inhibitor. The company is dedicated to making innovative cancer treatments more affordable and accessible, and it collaborates with various pharmaceutical firms to enhance its research and development efforts.

Nuevolution A/S is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. The company specializes in developing drug treatments for oncology and chronic inflammatory diseases. Nuevolution has created Chemetics®, an innovative drug discovery platform that combines wet chemistry and molecular biology to facilitate the rapid synthesis and screening of over one billion small molecule compounds. This technology allows for the efficient identification of potent drug candidates. The company's pipeline includes several programs such as ROR?t inhibitors and IL-17A inhibitors aimed at treating various diseases. Nuevolution collaborates with major pharmaceutical and biotechnology companies, entering into agreements with firms like Amgen and GlaxoSmithKline. Additionally, the company engages in contract research services, contributing to its revenue generation across multiple markets including Denmark, Sweden, and the USA. As a privately owned entity, Nuevolution is supported by key Scandinavian investors.

Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.

Darmiyan, Inc. is a company that specializes in the development of diagnostic software aimed at the early detection and monitoring of Alzheimer's disease and other neurodegenerative disorders. Based in San Francisco and founded in 2014, the company offers BrainSee, a Software as a Service platform that utilizes non-invasive brain MRI scans to produce detailed brain maps. This innovative tool quantifies neurodegeneration in individual brain voxels and generates a summary score reflecting brain health and the risk of cognitive decline. BrainSee operates using proprietary technology, referred to as The Virtual Microscope, which provides insights into brain cell distortion before clinical symptoms manifest. The algorithm has undergone successful third-party validation in the US and Canada, demonstrating its accuracy in predicting mild cognitive impairment. By leveraging advanced medical imaging and artificial intelligence, Darmiyan aims to enhance early diagnosis and intervention for patients with neurodegenerative diseases.

SiteOne, Inc. is a biotechnology company focused on developing innovative therapeutics and diagnostics for the treatment of acute and chronic pain. Established in 2010 and based in Bozeman, Montana, the company aims to provide safe and effective alternatives to existing pain management therapies, including nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. SiteOne's lead therapeutic candidates are selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is essential for transmitting pain signals in the nervous system. By targeting this specific channel, SiteOne seeks to offer new solutions for patients suffering from various pain conditions.

eHealth Ventures is a consortium conceived to provide incubation services to promising early-stage healthcare technology companies in Israel. The Government of Israel offers a unique opportunity for leverage by providing significant financial incentives to incubators assisting technology start-ups capitalizing on Israel's extraordinarily rich talent pool. The next Tender is expected the second half of 2014. eHealth Ventures will apply for an eight-year license under the program. They are seeking qualified individual and institutional investors who would like to participate in this extraordinary, highly leveraged opportunity.

Unilife is a U.S.-based medical device and technology company that specializes in designing, developing, and manufacturing innovative delivery systems for injectable drugs and vaccines. The company has created a drug delivery platform that features smart, reusable auto-injectors, allowing patients to control the speed of injection. This technology enhances the delivery of therapies packaged in standard prefilled barrels, catering to the needs of pharmaceutical and biotechnology companies that produce injectable biologics, drugs, and vaccines. Unilife's focus on differentiated delivery systems aims to improve patient experiences and outcomes in medication administration.

In April 2010, Medigene assigned its development program of oncolytic (cancer-killing) herpes simplex viruses (oHSV), to Catherex, Inc.

Dezima Pharma B.V., founded in 2012 and based in Naarden, the Netherlands, focuses on developing protein-based compounds for the treatment of cardiovascular diseases associated with dyslipidemia. The company specializes in creating novel drugs, including a cholesteryl ester transfer protein inhibitor, aimed at lowering low-density lipoprotein cholesterol levels. By addressing these lipid imbalances, Dezima Pharma provides clinicians with pharmacological therapies that can effectively treat patients suffering from dyslipidemic-related cardiovascular conditions.

Onyx Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company's lead product, Nexavar (sorafenib), is an oral multiple kinase inhibitor that targets proteins associated with tumor cell growth and blood vessel formation. By aiming to improve the lives of individuals affected by cancer, Onyx Pharmaceuticals is dedicated to advancing cancer care through its therapeutic offerings.

DeCODE Genetics is a biopharmaceutical company based in Reykjavik, Iceland, established in 1996. It specializes in analyzing the human genome to identify genetic variants associated with common diseases. The company conducts population studies to uncover key genetic risk factors for various health conditions, including cardiovascular disease and cancer. DeCODE Genetics develops diagnostic tests and technologies aimed at improving the treatment, diagnosis, and prevention of these diseases. By leveraging its expertise in chemistry and structural biology, the company supports the healthcare sector in offering DNA-based reference laboratory tests and consumer genome analysis services, which help assess individual disease risk.

MN is the leading supplier of pharmaceuticals to hospitals in Turkey and garnered sales of about $200 million last year, according to the statement. It was the first Turkish pharmaceutical company to win a license from the Food and Drug Administration to sell products in the U.S.

KAI Pharmaceuticals is a drug discovery and development company focused on creating innovative therapeutics for cardiovascular disease, kidney disease, and pain management. The company's lead product candidate, KAI-9803, is undergoing a Phase 2b clinical trial aimed at evaluating its ability to reduce myocardial injury in patients experiencing heart attacks. Additionally, KAI is advancing its second core program, KAI-4169, which targets secondary hyperparathyroidism in kidney disease patients and is anticipated to enter human clinical trials. The company is also exploring pain management through its ongoing program, KAI-1678, currently in Phase 2a testing.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.

Develops drugs focused on serious diseases

Laboratorio Quimico Farmaceutico Bergamo is operates as a pharmaceutical company.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Alantos Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery and development of small molecule drugs. Founded in 2002, the company focuses on creating treatments for conditions such as osteoarthritis, inflammation, and type II diabetes. Among its offerings are Dipeptidyl and Peptidase IV inhibitors, which contribute to various therapeutic pathways. Alantos Pharmaceuticals also explores potential treatments for rheumatoid arthritis, liver fibrosis, cardiovascular diseases, chronic wound healing, and cancer, showcasing its commitment to addressing a broad range of health challenges.

It discovers and develops renal care pharmaceutical products. It develops non-absorbed polymeric phosphate and potassium binder compounds to treat chronic kidney diseases. The company, formerly known as Symyx Therapeutics, Inc. was founded in 2002 and is based in Santa Clara, California.

Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California.

Abgenix is a biopharmaceutical company engaged in the discovery, development, and manufacture of human therapeutic antibodies for the treatment of various disease conditions such as cancer, inflammation, and metabolic disease. Its antibody therapeutic product candidates, which are in clinical trials include Panitumumab (ABX-EGF), a human antibody therapeutic product candidate directed against the epidermal growth factor receptor and a candidate for the treatment of various solid tumors. It also includes ABX-10241 (ABX-PTH), which isa fully human antibody therapeutic product candidate directed against parathyroid hormone for the treatment of a secondary hyper-para-thyroidism. Abgenix was established in 1996 and is headquartered in Fremont, California. It currently operates as a subsidiary of Amgen, Inc.

Tularik engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company is considered a pioneer in the field of cell signaling and the control of gene expression. The company is focused primarily of three main areas; inflammation, metabolic diseases and oncology. Tularik was founded by David Goeddel along with Steve McKnight and Robert Tjian in 1991. The company was acquired by Amgen for US$ 1.3 billion in 2004.

Immunex Corporation is a biopharmaceutical company based in Seattle, Washington, that focuses on the development, manufacturing, and marketing of therapeutic products aimed at treating cancer, infectious diseases, and autoimmune disorders. Founded in 1981, the company is known for its notable products, including Enbrel, which treats rheumatoid arthritis, Novantrone for acute nonlymphocytic leukemia and prostate cancer-related pain, and Leukine for bone marrow transplant patients. Immunex utilizes immune system proteins that function as hormones to provide these therapies. The company had a strategic alliance with American Home Products and, in 2002, was acquired by Amgen, Inc.

Filgrastim and pegfilgrastim are a supportive part of treatment for many patients receiving cancer chemotherapy. Some cancer drugs, in addition to attacking the cancer, destroy the patient's white blood cells, which are extremely important in fighting infection. Consequently, these patients are prone to developing severe, and even life-threatening, infections. Filgrastim and pegfilgrastim restore the number of white blood cells and thus improve their ability to kill infecting micro-organisms.

A company that specializes in discovering small molecules in the field of protein kinase inhibition.

Synergen provides revenue cycle management optimization solutions, consulting services, and analytics tailored for the healthcare industry. Founded in 2011 and based in Dallas, Texas, the company leverages technology and expertise to help healthcare organizations maximize their revenue potential. Synergen's offerings include a software platform that integrates patient information management, billing automation, and healthcare data analytics, designed to streamline and enhance revenue cycle processes. By simplifying complex financial data through user-friendly executive dashboards, Synergen enables healthcare providers to achieve quality outcomes and improve economic value. The company has experienced significant growth and has diversified its expertise to serve various specialties and large enterprise clients effectively.